Clinical Trials Logo

Multiple Myeloma in Relapse clinical trials

View clinical trials related to Multiple Myeloma in Relapse.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04861480 Enrolling by invitation - Clinical trials for Multiple Myeloma in Relapse

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Start date: June 16, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of C-4-29 in patients with relapsed or refractory multiple myeloma, and to obtain the maximum tolerated dose of C-4-29 and phase II Recommended dose.